Pharmaceutical Law | IP Enforcement | Medical Safety

On August 5, 2025, Danish pharmaceutical giant Novo Nordisk announced the launch of 14 new lawsuits in the United States against providers of unapproved compounded semaglutide—the active ingredient in its blockbuster weight-loss and diabetes treatments, Wegovy and Ozempic (Reuters). The litigation targets compounding pharmacies, telehealth firms, and medical spas accused of selling knockoff versions misrepresented as personalized medicines.

What the Lawsuits Allege

Novo Nordisk claims these defendants:

• Marketed compounded semaglutide under false claims of FDA approval or equivalence to the branded drugs
• Used the pretext of “personalization” to steer patients toward unsafe, unapproved products
• Violated state corporate practice of medicine laws by influencing prescribing decisions improperly (Reuters, StreetInsider.com).

The lawsuits warn that many compounded products use illicit foreign active pharmaceutical ingredients (API), raising safety concerns in contrast to FDA-approved manufacturing standards. These legal actions follow FDA warnings about serious health risks tied to compounded GLP‑1 drugs, including hospitalizations and deaths (Comtex News).

Enforcement Scale: A Nationwide Campaign

This latest wave is part of Novo’s wider legal strategy: the company has filed over 130 lawsuits in more than 40 states, securing at least 44 permanent injunctions that restrict the marketing and sale of unapproved semaglutide products (Seeking Alpha). Notably, these include companies previously sued by competitors such as Eli Lilly over similar practices involving tirzepatide-based products.

Interestingly, Hims & Hers, a high-profile telehealth firm, has not been sued in this round, though its shares fell after revenue disappointments tied in part to legal exposure (Reuters).

Legal Issues Underlying the Litigation

1. FDA Preemption & Compounding Rules

Under federal law, compounding pharmacies may prepare customized drugs when a medicine is listed as in shortage. While semaglutide was declared in shortage through May 2025, FDA removed it from that list earlier in the year, meaning compounded versions are no longer legally permitted (CNBC).

2. Intellectual Property & Competition Law

Novo’s claims encompass trademark infringement and unfair competition, asserting that compounders are misappropriating the semaglutide name and undercutting market exclusivity through misleading narratives tied to personalization (Investing.com Canada, Healthcare Middle East & Africa).

3. Patient Safety and State Licensing

The lawsuits highlight patient safety risks—notably contamination, incorrect dosing, and banned substances in compounded drugs—contrasted with rigorous FDA review required for branded products. Novo argues that telehealth entities improperly influence prescribing and improperly practice medicine under state law (Investing.com Canada, PR Newswire).

What This Means for Pharma, Telehealth, and Regulators

Patient Safety Imperative

The litigation underscores concerns over compounded drugs made with non‑FDA‑approved foreign APIs, with reported cases of serious adverse reactions. Novo asserts at least ten deaths and 100+ hospitalizations tied to compounded semaglutide (Reddit).

Telehealth Accountability

By challenging state “corporate practice of medicine” norms, Novo’s lawsuits raise questions about the legal boundaries of telehealth companies marketing pharmaceuticals—especially when they influence prescriber behavior without licensed practitioner oversight.

IP and Anti-Competitive Enforcement

Novo’s coordinated litigation signals a new approach: combining intellectual property claims, consumer protection, and medical licensing theories to protect brand integrity and market exclusivity.

Regulatory Reinforcement

As the FDA moves to enforce against unauthorized compounders post-shortage, the company’s legal precedents may reinforce the agency’s authority and guide future policy on emerging health products and direct-to-patient telehealth models.

Legal Outlook and Key Considerations

• Federal injunctions and litigation outcomes will help define permissible limits of drug compounding in post-shortage contexts.
• State court rulings on telehealth prescribing practices could set influential precedents beyond semaglutide.
• Market impacts include potential decline in compounders, shifts toward more affordable access to branded drugs, and renewed scrutiny of GLP-1 medication over-prescription or misuse.
• Broader consequences extend to how drugmakers challengers protect patents and trademarks in the digital and compounding era.

Conclusion: Future of Pharmaceutical Regulation

Novo Nordisk’s aggressive U.S. litigation campaign—from 14 lawsuits filed on August 5, 2025 to over 130 actions nationwide—reflects escalating tension between branded pharmaceutical control, patient safety, and emerging telehealth-compounding trends. The outcome could reshape not only semaglutide markets, but also the future regulatory landscape for digital prescribing, drug compounding, and pharmaceutical IP enforcement.